Literature DB >> 11706079

Immunohistochemical [corrected] detection of the alternate INK4a-encoded tumor suppressor protein p14(ARF) in archival human cancers and cell lines using commercial antibodies: correlation with p16(INK4a) expression.

J Geradts1, R E Wilentz, H Roberts.   

Abstract

The INK4a locus encodes two structurally unrelated tumor suppressor proteins, p16(INK4a) and p14(ARF). Although the former is one of the most common targets for inactivation in human neoplasia, the frequency of p14(ARF) abrogation is not established. We have developed an immunohistochemical assay that allows the evaluation of p14(ARF) expression in formalin-fixed, paraffin-embedded tissues, using commercially available antibodies. p14(ARF) positive cells showed nuclear/nucleolar staining, which was absent in all cell lines and tumors with homozygous deletions of the INK4a gene. The assay was applied to 34 paraffin-embedded cell buttons, 30 non-small cell lung cancers and 28 pancreatic carcinomas, and the staining results were correlated with p16(INK4a) expression. Loss of p14(ARF) expression was common but less frequent than down-regulation of p16(INK4a) (53% versus 76% of all specimens). The p14(ARF) and p16(INK4a) expression pattern was concordant in 65 of 92 cases (71%). Significantly, 24 cases were p16(INK4a)-/p14(ARF)+, while the opposite staining pattern was observed in three cases, consistent with the notion that the two proteins have nonredundant functions. The immunohistochemical assay described here may facilitate studies on the prevalence and significance of aberrant p14(ARF) expression in human tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11706079     DOI: 10.1038/modpathol.3880452

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  7 in total

Review 1.  Roles of ARF tumour suppressor protein in lung cancer: time to hit the nail on the head!

Authors:  Ruju Vashi; Bhoomika M Patel
Journal:  Mol Cell Biochem       Date:  2021-01-03       Impact factor: 3.396

Review 2.  p53 and ARF: unexpected players in autophagy.

Authors:  Gregor M Balaburski; Robert D Hontz; Maureen E Murphy
Journal:  Trends Cell Biol       Date:  2010-03-19       Impact factor: 20.808

3.  Alterations of ubiquitylation and sumoylation in conventional renal cell carcinomas after the Chernobyl accident: a comparison with Spanish cases.

Authors:  Luisa Morell-Quadreny; Alina Romanenko; Jose Antonio Lopez-Guerrero; Silvia Calabuig; Alexander Vozianov; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2011-07-23       Impact factor: 4.064

4.  The status of CDKN2A alpha (p16INK4A) and beta (p14ARF) transcripts in thyroid tumour progression.

Authors:  A Ferru; G Fromont; H Gibelin; J Guilhot; F Savagner; J M Tourani; J L Kraimps; C J Larsen; L Karayan-Tapon
Journal:  Br J Cancer       Date:  2006-11-21       Impact factor: 7.640

5.  p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.

Authors:  S B Vestey; C Sen; C J Calder; C M Perks; M Pignatelli; Z E Winters
Journal:  Breast Cancer Res       Date:  2004-07-29       Impact factor: 6.466

6.  Peptide-based tumor inhibitor encoding mitochondrial p14(ARF) is highly efficacious to diverse tumors.

Authors:  Ken Saito; Hidekazu Iioka; Chie Kojima; Mikako Ogawa; Eisaku Kondo
Journal:  Cancer Sci       Date:  2016-08-04       Impact factor: 6.716

7.  p16, pRb, and p53 in Feline Oral Squamous Cell Carcinoma.

Authors:  Wachiraphan Supsavhad; Wessel P Dirksen; Blake E Hildreth; Thomas J Rosol
Journal:  Vet Sci       Date:  2016-08-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.